NJ State Employees Deferred Compensation Plan’s Alnylam Pharmaceuticals ALNY Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,000	Closed	-$243K	–	475
2024 Q2	$243K	Buy	+1,000	New	+$158K	0.03%	397
2023 Q2	–	Sell	-1,000	Closed	-$200K	–	488
2023 Q1	$200K	Hold	1,000	–	–	0.03%	439
2022 Q4	$238K	Hold	1,000	–	–	0.04%	400
2022 Q3	$200K	Buy	+1,000	New	+$191K	0.03%	416

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's ALNY Position: Q3 2024 in Review

NJ State Employees Deferred Compensation Plan sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2024, closing a stake of 1,000 shares — an estimated $243K sold.

NJ State Employees Deferred Compensation Plan first reported a position in ALNY in Q3 2022 and held it in 4 quarters. The position peaked at $243K in Q2 2024. 567 funds tracked by Wall St. Rank hold ALNY as of Q3 2024.

NJ State Employees Deferred Compensation Plan reported no remaining Alnylam Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 1,000 Alnylam Pharmaceuticals shares in Q3 2024, an estimated $243K.
NJ State Employees Deferred Compensation Plan first reported a position in Alnylam Pharmaceuticals in Q3 2022 and held it in 4 quarters.
NJ State Employees Deferred Compensation Plan's Alnylam Pharmaceuticals position peaked at $243K in Q2 2024.
567 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2024.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q3 2024, filed 4 Nov 2024.